Atossa Genetics Inc Stock
Atossa Genetics Inc Stock
A loss of -1.890% shows a downward development for Atossa Genetics Inc.
We see a rather positive sentiment for Atossa Genetics Inc with 7 Buy predictions and 1 Sell predictions.
Based on the current price of 1.46 € the target price of 3 € shows a potential of 106.04% for Atossa Genetics Inc which would more than double the current price.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Atossa Genetics Inc stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Atossa Genetics Inc in the next few years
Pros
?
G***** c******* t* c**********
?
B****
?
W********* I********* f** t** n*** y****
Cons
?
C******** o* t** e**********
?
M***** P*******
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Atossa Genetics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Atossa Genetics Inc | -1.890% | -5.357% | -8.055% | 127.782% | 57.705% | -38.038% | -60.363% |
| InVivo Therapeutics Holdings | -0.600% | -0.599% | 0.606% | -72.007% | -51.744% | -99.930% | -99.957% |
| Star Equity Holdings Inc. | -0.610% | -5.202% | -0.606% | 7.190% | -12.766% | -61.682% | -86.753% |
| Medmira Inc. | - | 0.000% | 12.121% | -9.756% | -14.615% | - | - |
Comments
Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Show more
Ratings data for ATOS provided by MarketBeat
Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its price target raised by analysts at HC Wainwright from $4.00 to $6.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ATOS provided by MarketBeat
Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
Show more
Ratings data for ATOS provided by MarketBeat